Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
Amgen, Thousand Oaks, CA 91320, USA. public@robertsikorski.com
It is within pivotal phase III clinical trials that predictive biomarkers have the greatest potential to affect clinical practice by targeting drugs under development to relevant patient subgroups. Predictive biomarkers can be integrated into phase III clinical trials by a variety of approaches, including trial designs that uncouple the processes and actively anticipate the emergence of new biomarkers during trial execution. Here we describe the various approaches in an oncology context.
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on